REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · IEX Real-Time Price · USD
22.70
+0.01 (0.04%)
Nov 29, 2022 3:19 PM EDT - Market open
0.04%
Market Cap 1.01B
Revenue (ttm) 480.03M
Net Income (ttm) 73.64M
Shares Out 43.25M
EPS (ttm) 1.74
PE Ratio 13.05
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,573
Open 22.57
Previous Close 22.69
Day's Range 22.44 - 23.08
52-Week Range 18.69 - 36.35
Beta 0.99
Analysts Buy
Price Target 49.06 (+116.1%)
Earnings Date Nov 3, 2022

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is ... [Read more]

Industry Biotechnology
IPO Date Sep 17, 2015
CEO Kenneth Mills
Employees 372
Stock Exchange NASDAQ
Ticker Symbol RGNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is 49.06, which is an increase of 116.12% from the latest price.

Price Target
$49.06
(116.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conf...

1 week ago - PRNewsWire

Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 RGX-314 program for the treatment ...

3 weeks ago - PRNewsWire

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatm...

RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events Patients treated with RGX-314 in Cohorts 1-3 demonstrated clinically meaningful improve...

3 weeks ago - PRNewsWire

REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational H...

ROCKVILLE, Md. , Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal delivery ...

1 month ago - PRNewsWire

What's a Fun-Sized Stock? Around $1 Billion

A company with a market value of about $1 billion is small enough to grow fast, yet large enough so that it can begin to appeal to institutional investors such as pension funds.

1 month ago - GuruFocus

REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD

Company announced positive interim data from and the expansion of Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery   RGX-314 continues to be well tolerated i...

1 month ago - PRNewsWire

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

ROCKVILLE, Md. , Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, Oct...

2 months ago - PRNewsWire

REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting

Company to host conference call on Monday, October 3 rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE® trial ROCKVILLE, Md.

2 months ago - PRNewsWire

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treat...

-       New data in Cohort 3 using pivotal program dose level demonstrates largest median reduction in CSF GAGs, continuing to approach normal levels at 48 weeks -       RGX-121, a one-time gene therapy...

2 months ago - PRNewsWire

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

ROCKVILLE, Md. , Aug. 23, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place from...

3 months ago - PRNewsWire

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ROCKVILLE, Md. , Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C.

3 months ago - PRNewsWire

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -9.72% and 25.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOS...

3 months ago - PRNewsWire

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-...

FDA will consider an accelerated approval pathway for RGX-121; BLA filing expected in 2024 Pivotal program is active and enrolling patients RGX-121 is a potential first-in-class, one-time gene therapy f...

3 months ago - PRNewsWire

Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational...

ROCKVILLE, Md. , Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m.

3 months ago - PRNewsWire

REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

85 subjects dosed across five cohorts in AAVIATE ®  trial evaluating RGX-314 for the treatment of wet AMD using suprachoroidal delivery Company expects to report additional suprachoroidal data later thi...

4 months ago - PRNewsWire

REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility

In-house facility to produce NAV Technology-based AAV gene therapies at 2,000 liters scale $65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery C...

5 months ago - PRNewsWire

Jennifer Zachary Joins REGENXBIO Board of Directors

ROCKVILLE, Md. , June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022.

5 months ago - PRNewsWire

5 Small-Cap S&P Stocks To Buy With The Most Upside

The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-ca...

Other symbols: AXLCYHTGITREE
6 months ago - Benzinga

Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , May 4, 2022 /PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024 Enrollment ongoing ...

6 months ago - PRNewsWire

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

ROCKVILLE, Md. , May 3, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtuall...

6 months ago - PRNewsWire

3 Small-Cap Medical Stocks With Big Momentum

Now is a good time to take a closer look at these stocks.

Other symbols: CORTPCRX
7 months ago - The Motley Fool